AstraZeneca has entered into a multi-year agreement with Galapagos subsidiaries BioFocus and Argenta to collaborate on discovery of compounds for the treatment of respiratory and inflammatory diseases. The deal allows AstraZeneca the use of Argenta’s respiratory models, including those for asthma, COPD, and inflammation. The companies did not disclose the financial details of the agreement.
Galapagos Services Senior VP Chris Newton said, “Both BioFocus and Argenta have worked extensively with AstraZeneca over the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on. We are delighted to renew our new drug discovery alliance with one of the world’s leading research-based pharmaceutical companies.”
“We continue to be impressed by the strength of the BioFocus and Argenta technology platforms and the evident depth of experience of the scientists that will be engaged on our projects addressing respiratory and inflammatory conditions,” added AstraZeneca VP of Respiratory and Inflammatory Innovative Medicines Science Unit John Steele.
Read the Argenta press release.
